Postmortem studies in Parkinson's disease

Dialogues in Clinical Neuroscience

Volumn 6, Issue 3, 2004, Pages 281-293

  Hartmann, Andreas ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Cellular stress; Dopaminergic neuron; Etiology; Lewy body formation; Parkinson's disease; Pathogenesis; Postmortem study

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALPHA SYNUCLEIN; AMINO ACID TRANSFER RNA LIGASE; CALBINDIN; CASPASE 3; CYTOKINE; DOPAMINE TRANSPORTER; ENDOTHELIN RECEPTOR; FAS ASSOCIATED DEATH DOMAIN PROTEIN; GAMMA INTERFERON; HEAT SHOCK PROTEIN; INTERLEUKIN 1BETA; MEMBRANE PROTEIN; PARKIN; PARKIN ASSOCIATED ENDOTHELIN LIKE RECEPTOR; PROTEASOME; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; SYNPHILIN 1; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; UBIQUITIN; UNCLASSIFIED DRUG; VESICULAR MONOAMINE TRANSPORTER 2; VESICULAR TRANSPORT PROTEIN;

APOPTOSIS; ARTICLE; AUTOPSY; CENTRAL GRAY MATTER; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; ENVIRONMENTAL FACTOR; GENETICS; HUMAN; HUMAN TISSUE; INFECTION; INFLAMMATION; LEWY BODY; MESENCEPHALON; NIGRONEOSTRIATAL SYSTEM; NOCARDIA ASTEROIDES; OXIDATIVE STRESS; PARKINSON DISEASE;

EID: 5444225223     PISSN: 12948322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (136)

1. Carlsson A. The occurrence, distribution and physiological role of catecholamines in the nervous system. Pharmacol Rev. 1959;11(2, Part 2):490-493.
2. Ehringer H, Hornykiewicz O. Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system [in German]. Klin Wochenschr. 1960;38:1236-1239.
3. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci. 1973;20:415-455.
4. Hirsch E, Graybiel AM, Agid YA. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature. 1988;334:345-348.
5. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science. 1997;276:2045-2047.
6. Kitada T, Asakawa S, Hattori N, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature. 1998;392:605-608.
7. Bonifati V, Rizzu P, van Baren MJ, et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science. 2003;299:256-259.
8. Leroy E, Boyer R, Auburger G, et al. The ubiquitin pathway in Parkinson's disease. Nature. 1998;395:451-452.
9. Maraganore DM, Lesnick TG, Elbaz A, et al. UCHL1 is a Parkinson's disease susceptibility gene. Ann Neurol. 2004;55:512-521.
10. Krüger R, Kuhn W, Muller T, et al. Ala30Pro mutation in the gene encoding a-synuclein in Parkinson's disease. Nat Genet. 1998;18:106-108.
11. Zarranz JJ, Alegre J, Gomez-Esteban JC, et al. The new mutation, E46K, of α-synuclein causes Parkinson and Lewy body dementia. Ann Neurol. 2004;55:164-173.
12. Farrer M, Maraganore DM, Lockhart P, et al. α-Synuclein gene haplotypes are associated with Parkinson's disease. Hum Mol Genet. 2001;10:1847-1851.
13. Tan EK, Tan C, Shen H, et al. Asynuclein promoter and risk of Parkinson's disease: microsatellite and allelic size variability. Neurosci Lett. 2003;336:70-72.
14. Holzmann C, Kruger R, Saecker AM, et al. Polymorphisms of the α-synuclein promoter: expression analyses and association studies in Parkinson's disease. J Neural Transm. 2003;110:67-76.
15. Farrer M, Kachergus J, Forno L, et al. Comparison of kindreds with parkinsonism and α-synuclein genomic multiplications. Ann Neurol. 2004;55:174-179.
16. Singleton AB, Farrer M, Johnson J, et al. α-Synuclein locus triplication causes Parkinson's disease. Science. 2003;302:841.
17. Rockenstein E, Hansen LA, Mallory M, et al. Altered expression of the synuclein family mRNA in Lewy body and Alzheimer's disease. Brain Res. 2000;914:48-56.
18. Arima K, Hirai S, Sunohara N, et al. Cellular co-localization of phosphorylated tau- and NACP/α-synuclein-epitopes in Lewy bodies in sporadic Parkinson's disease and in dementia with Lewy bodies. Brain Res. 1999;843:53-61.
19. Baba M, Nakajo S, Tu PH, et al. Aggregation of α-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am J Pathol. 1998;152:879-884.
20. Irizarry MC, Growdon W, Gomez-Isla T, et al. Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain α-synuclein immunoreactivity. J Neuropathol Exp Neurol. 1998;57:334-337.
21. Mezey E, Dehejia AM, Harta G, et al. A synuclein is present in Lewy bodies in sporadic Parkinson's disease. Mol Psychiatry. 1998;3:493-499.
22. Spillantini MG, Crowther RA, Jakes R, et al. α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci USA. 1998;95:6469-6473.
23. Hill WD, Lee VM, Hurtig HI, Murray JM, Trojanowski JQ. Epitopes located in spatially separate domains of each neurofilament subunit are present in Parkinson's disease Lewy bodies. J Comp Neurol. 1991;309:150-160.
24. Ishizawa T, Mattila P, Davies P, Wang D, Dickson DW. Colocalization of tau and α-synuclein epitopes in Lewy bodies. J Neuropathol Exp Neurol. 2003;62:389-397.
25. Lowe J, McDermott H, Landon M, Mayer RJ, Wilkinson KD. Ubiquitin carboxyl-terminal hydrolase (PGP 9.5) is selectively present in ubiquitinated inclusion bodies characteristic of human neurodegenerative diseases. J Pathol. 1990;161:153-160.
26. Pollanen MS, Dickson DW, Bergeron C. Pathology and biology of the Lewy body. J Neuropathol Exp Neurol. 1993;52:183-191.
27. Forno LS, DeLanney LE, Irwin I, et al. Electron microscopy of Lewy bodies in the amygdala-parahippocampal region. Comparison with inclusion bodies in the MPTP-treated squirrel monkey. Adv Neurol. 1996;69:217-228.
28. Good PF, Hsu A, Werner P, et al. Protein nitration in Parkinson's disease. J Neuropathol Exp Neurol. 1998;57:338-342.
29. Giasson BI, Duda JE, Murray IV, et al. Oxidative damage linked to neurodegeneration by selective a-synuclein nitration in synucleinopathy lesions. Science. 2000;290:985-989.
30. Shashidharan P, Good PF, Hsu A, et al. TorsinA accumulation in Lewy bodies in sporadic Parkinson's disease. Brain Res. 2000;877:379-381.
31. Schlossmacher MG, Frosch MP, Gai WP, et al. Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies. Am J Pathol. 2002;160:1655-1667.
32. Murakami T, Shoji M, Imai Y, et al. Pael-R is accumulated in Lewy bodies of Parkinson's disease. Ann Neurol. 2004;55:439-442.
33. Wakabayashi K, Engelender S, Yoshimoto M, Tsuji S, Ross CA, Takahashi H. Synphilin-1 is present in Lewy bodies in Parkinson's disease. Ann Neurol. 2000;47:521-523.
34. Corti O, Hampe C, Koutnikova H, et al. The p38 subunit of the aminoacyl-tRNA synthetase complex is a Parkin substrate: linking protein biosynthesis and neurodegeneration. Hum Mol Genet. 2003;12:1427-1437.
35. Lee SS, Kim YM, Junn E, et al. Cell cycle aberrations by α-synuclein overexpression and cyclin B immunoreactivity in Lewy bodies. Neurobiol Aging. 2003;24:687-696.
36. Junn E, Ronchetti RD, Quezado MM, Kim SY, Mouradian MM. Tissue transglutaminase-induced aggregation of α-synuclein: implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci U S A. 2003;100:2047-2052.
37. Zarate-Lagunes M, Gu WJ, Blanchard V, et al. Parkin immunoreactivity in the brain of human and non-human primates: an immunohistochemical analysis in normal conditions and in parkinsonian syndromes. J Comp Neurol. 2001;432:184-196.
38. Shimura H, Hattori N, Kubo S, et al. Immunohistochemical and subcellular localization of Parkin protein: absence of protein in autosomal recessive juvenile parkinsonism patients. Ann Neurol. 1999;45:668-672.
39. Hayashi S, Wakabayashi K, Ishikawa A, et al. An autopsy case of autosomal-recessive juvenile parkinsonism with a homozygous exon 4 deletion in the parkin gene. Mov Disord. 2000;15:884-888.
40. Farrer M, Chan P, Chen R, et al. Lewy bodies and parkinsonism in families with parkin mutations. Ann Neurol. 2001;50:293-300.
41. Bandopadhyay R, Kingsbury AE, Cookson MR, et al. The expression of DJ-1 (PARK7) in normal human CNS and idiopathic Parkinson's disease. Brain. 2004;127(Pt 2):420-430.
42. Rizzu P, Hinkle DA, Zhukareva V, et al. DJ-1 colocalizes with tau inclusions: a link between parkinsonism and dementia. Ann Neurol. 2004;55:113-118.
43. Conway KA, Lee SJ, Rochet JC, et al. Acceleration of oligomerization, not fibrillization, is a shared property of both α-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc Natl Acad Sci U S A. 2000;97:571-576.
44. Conway KA, Pchet JC, Bieganski RM, et al. Kinetic stabilization of α-synuclein protofibril by dopamine-α-synuclein adduct. Science. 2001;294:1346-1349.
45. Tompkins MM, Hill WD. Contribution of somal Lewy bodies to neuronal death. Brain Res. 1997;775:24-29.
46. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry. 1988;51:745-752.
47. Gertz HJ, Siegers A, Kuchinke J. Stability of cell size and nucleolar size in Lewy body containing neurons of substantia nigra in Parkinson's disease. Brain Res. 1994;637:339-341.
48. Patt S, Gertz HJ, Gerhard L, et al. Pathological changes in dendrites of substantia nigra neurons in Parkinson's disease: a Golgi study. Histol Histopathol. 1991;6:373-380.
49. Hill WD. Altered neurofilament expression does not contribute to Lewy body formation. Am J Pathol. 1996;149:728-729.
50. Hartmann A, Hunot S, Michel PP, et al. Caspase-3: a vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease. Proc Natl Acad Sci USA. 2000;97:2875-2880.
51. Hartmann A, Hirsch EC. Parkinson's disease. The apoptosis hypothesis revisited. Adv Neurol. 2001;86:143-153.
52. Galvin JE, Lee VM, Schmidt ML, Tu PH, Iwatsubo T, Trojanowski JQ. Pathobiology of the Lewy body. Adv Neurol. 1999;80:313-324.
53. Tu PH, Robinson KA, de Snoo F, et al. Selective degeneration of Purkinje cells with Lewy body-like inclusions in aged NFHLACZ transgenic mice. J Neurosci. 1997;17:1064-7104.
54. Hurtig HI, Trojanowski JQ, Galvin J, et al. α-Synuclein cortical Lewy body correlate with dementia in Parkinson's disease. Neurology. 2000;54:1916-1921.
55. Mattila PM, Rinne JO, Helenius H, et al. α-Synuclein-immunoreactive cortical impairment in Parkinson's disease. Acts Neuropathol (Berl). 2000;100:285-290.
56. Hirsch EC, Orieux G, Muriel MP, Francois C, Feger J. Nondopaminergic neurons in Parkinson's disease. Adv Neurol. 2003;91:29-37.
57. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain. 1991;114(Pt 5):2283-2301.
58. Damier P, Hirsch EC, Agid Y, Graybiel AM. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain. 1999;122(Pt 8):1437-1448.
59. Damier P, Hirsch EC, Agid Y, Graybiel AM. The substantia nigra of the human brain. I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D(28K) immunohistochemistry. Brain. 1999;122(Pt 8):1421-1436.
60. German DC, Manaye KF, Sonsalla PK, et al. Midbrain dopaminergic cell loss in Parkinson's disease and MPTP-induced parkinsonism: sparing of calbindin-D28k-containing cells. Ann N Y Acad Sci. 1992;648:42-62.
61. Gaspar P, Ben Jelloun N, Febvret A. Sparing of the dopaminergic neurons containing calbindin-D28k and of the dopaminergic mesocortical projections in weaver mutant mice. Neuroscience. 1994;61:293-305.
62. Liang CL, Sinton CM, German DC. Midbrain dopaminergic neurons in the mouse: co-localization with calbindin-D28K and calretinin. Neuroscience. 1996;75:523-533.
63. Iacopino AM, Christakos S. Specific reduction of calcium-binding protein (28-kilodalton calbindin-D) gene expression in aging and neurodegenerative diseases. Proc Natl Acad Sci USA. 1990;87:4078-4082.
64. Airaksinen MS, Thoenen H, Meyer M. Vulnerability of midbrain dopaminergic neurons in calbindin-D28k-deficient mice: lack of evidence for a neuroprotective role of endogenous calbindin in MPTP-treated and weaver mice. Eur J Neurosci. 1997;9:120-127.
65. Sanghera MK, Manaye K, McMahon A, Sonsalla PK, German DC. Dopamine transporter mRNA levels are high in midbrain neurons vulnerable to MPTP. Neuroreport. 1997;8:3327-3331.
66. Uhl GR. Hypothesis: the role of dopaminergic transporters in selective vulnerability of cells in Parkinson's disease. Ann Neurol. 1998;43:555-560.
67. Miller GW, Erickson JD, Perez JT, et al. Immunochemical analysis of vesicular monoamine transporter (VMAT2) protein in Parkinson's disease. Exp Neurol. 1999;156:138-148.
68. Miller GW, Heilman CJ, Perez JT, et al. Immunochemical analysis of dopamine transporter protein in Parkinson's disease. Ann Neurol. 1997;41:530-539.
69. Shimada S, Kitayama S, Walther D, et al. Dopamine transporter mRNA: dense expression in ventral midbrain neurons. Mol Brain Res. 1992;13:359-362.
70. Uhl GR, Walther D, Mash D, et al. Dopamine transporter messenger RNA in Parkinson's disease and control substantia nigra neurons. Ann Neurol. 1994;35:494-498.
71. Wersinger C, Sidhu A. Attentuation of dopamine transporter activity by α-synuclein. Neurosci Lett. 2003;340:189-192.
72. Lee FJ, Liu F, Pristupa ZB, Niznik HB. Direct binding and functional coupling of α-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis. FASEB J. 2001;15:916-926.
73. Lotharius J, Brundin P. Pathogenesis of Parkinson's disease: dopamine, vesicles and α-synuclein. Nat Rev Neurosci. 2002;3:932-942.
74. Voges D, Zwickl P, Baumeister W. The 26S proteasome: a molecular machine designed for controlled proteolysis. Annu Rev Biochem. 1999;68:1015-1068.
75. Alam ZI, Daniel SE, Lees AJ, et al. A generalised increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease. J Neurochem. 1997;69:1326-1329.
76. McNaught KS, Jenner P. Proteasomal function is impaired in substantia nigra in Parkinson's disease. Neurosci Lett. 2001;297:191-194.
77. McNaught KS, Belezaire R, lsacson O, et al. Altered proteasomal function in Parkinson's disease. Exp Neurol. 2003;179:38-46.
78. Ardley HC, Scott GB, Rose SA, Tan NG, Markham AF, Robinson PA. Inhibition of proteasomal activity causes inclusion formation in neuronal and non-neuronal cells overexpressing parkin. Mol Biol Cell. 2003;14:4541-4556.
79. Tofaris GK, Razzaq A, Ghetti B, Lilley KS, Spillantini MG. Ubiquitination of α-synuclein in Lewy bodies is a pathological event not associated with impairment of proteasome function. J Biol Chem. 2003;278:44405-44411.
80. Kastner A, Hirsch EC, Lejeune O, Javoy-Agid F, Rascol O, Agid Y. Is the vulnerability of neurons in the substantia nigra of patients with Parkinson's disease related to their neuromelanin content? J Neurochem. 1992;59:1080-1089.
81. Yoritaka A, Hattori N, Uchida K, Tanaka M, Stadtman ER, Mizuno Y. Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc Natl Acad Sci U S A. 1996;93:2696-2701.
82. Floor E, Wetzel MG. Increased protein oxidation in human substantia nigra pars compacta in comparison with basal ganglia and prefrontal cortex measured with an improved dinitrophenylhydrazine assay. J Neurochem. 1998;70:268-275.
83. Kish SJ, Morito C, Hornykiewicz O. Glutathione peroxidase activity in Parkinson's disease brain. Neurosci Lett. 1985;58:343-346.
84. Jenner P, Dexter DT, Sian J, Schapira AH, Marsden CD. Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease. The Royal Kings and Queens Parkinson's Disease Research Group. Ann Neurol. 1992;32(suppl):S82-S87.
85. Damier P, Hirsch EC, Zhang P, Agid Y, Javoy-Agid F. Glutathione peroxidase, glial cells and Parkinson's disease. Neuroscience. 1993;52:1-6.
86. Dexter DT, Carter CJ, Wells FR, et al. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem. 1989;52:381-389.
87. Zhang J, Perry G, Smith MA, et al. Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons. Am J Pathol. 1999;154:1423-1429.
88. Lee SJ. α-Synuclein aggregation: a link between mitochondrial defects and Parkinson's disease? Antioxid Redox Signal. 2003;5:337-348.
89. Hunot S, Brugg B, Ricard D, et al. Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with Parkinson disease. Proc Natl Acad Sci U S A. 1997;94:7531-7536.
90. Sofic E, Riederer P, Heinsen H, et al. Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J Neurol Transm. 1988;74:199-205.
91. Dexter DT, Jenner P, Schapira AH, Marsden CD. Alterations in levels of iron, ferritin, and other trace metals in neurodegenerative diseases affecting the basal ganglia. The Royal Kings and Queens Parkinson's Disease Research Group. Ann Neurol. 1992;32(suppl):S94-S100.
92. Faucheux BA, Martin ME, Beaumont C, Hauw JJ, Agid Y, Hirsch EC. Neuromelanin associated redox-active iron is increased in the substantia nigra of patients with Parkinson's disease. J Neurochem. 2003;86:1142-1148.
93. Kaur D, Andersen JK. Ironing out Parkinson's disease: is therapeutic treatment with iron chelators a real possibility? Aging Cell. 2002;1:17-21.
94. Castellani RJ, Siedlak SL, Perry G, Smith MA. Sequestration of iron by Lewy bodies in Parkinson's disease. Acta Neuropathol (Berl). 2000;100:111-114.
95. Giasson BI, Duda JE, Murray IV, et al. Oxidative damage linked to neurodegeneration by selective α-synuclein nitration in synudeinopathy lesions. Science. 2000;290:985-989.
96. McGeer PL, McGeer EG. Mechanisms of cell death in Alzheimer disease-immunopathology. J Neural Transm Suppl. 1998;54:159-166.
97. McGeer PL, Schwab C, Parent A, Doudet D. Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine administration. Ann Neurol. 2003;54:599-604.
98. Hunot S, Hirsch EC. Neuroinflammatory processes in Parkinson's disease. Ann Neurol. 2003;53(suppl 3):S49-S58.
99. Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 1983;219:979-980.
100. Langston JW, Forno LS, Tetrud J, Reeves AG, Kaplan JA, Karluk D. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann Neurol. 1999;46:598-605.
101. Nagatsu T, Mogi M, Ichinose H, Togari A. Cytokines in Parkinson's disease. J Neural Transm Suppl. 2000;58:143-151.
102. Boka G, Anglade P, Wallach D, Javoy-Agid F, Agid Y, Hirsch EC. Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease. Neurosci Lett. 1994;172:151-154.
103. Hunot S, Dugas N, Faucheux B, et al. FcepsilonRII/CD23 is expressed in Parkinson's disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-α in glial cells. J Neurosci. 1999;19:3440-3447.
104. Hunot S, Boissiere F, Faucheux B, et al. Nitric oxide synthase and neuronal vulnerability in Parkinson's disease. Neuroscience. 1996;72:355-363.
105. McGeer PL, Itagaki S, Akiyama H, McGeer EG. Rate of cell death in parkinsonism indicates active neuropathological process. Ann Neurol. 1988;24:574-576.
106. Hurley SD, O'Banion MK, Song DD, Arana FS, Olschowka JA, Haber SN. Microglial response is poorly correlated with neurodegeneration following chronic, low-dose MPTP administration in monkeys. Exp Neurol. 2003;184:659-668.
107. Barcia C, Bahillo AS, Fernandez-Villaba E, et al. Evidence of active microglia in substantia nigra pars compacta of parkinsonian monkeys 1 year after MPTP exposure. Glia. 2004;46:402-409.
108. Tatton WG, Chalmers-Redman R, Brown D, Tatton N. Apoptosis in Parkinson's disease: signals for neuronal degradation. Ann Neurol. 2003;53(suppl 3):S61-S70. Discussion. S70-S72.
109. Kingsbury AE, Mardsen CD, Foster OJ. DNA fragmentation in human substantia nigra: apoptosis or perimortem effect? Mov Disord. 1998;13:877-884.
110. Green DR. Apoptotic pathways: the roads to ruin. Cell. 1998;94:695-698.
111. Hartmann A, Mouatt-Prigent A, Vila M, et al. Increased expression and redistribution of the antiapoptotic molecule Bcl-xL in Parkinson's disease. Neurobiol Dis. 2002;10:28-32.
112. Hartmann A, Troadec JD, Hunot S, et al. Caspase-8 is an effector in apoptotic death of dopaminergic neurons in Parkinson's disease, but pathway inhibition results in neuronal necrosis. J Neurosci. 2001;21:2247-2255.
113. Hartmann A, Michel PP, Troadec JD, et al. Is Bax a mitochondrial mediator in apoptotic death of dopaminergic neurons in Parkinson's disease? J Neurochem. 2001;76:1785-1793.
114. Tatton NA. Increased caspase 3 and Bax immunoreactivity accompany nuclear GAPDH translocation and neuronal apoptosis in Parkinson's disease. Exp Neurol. 2000;166:29-43.
115. Hartmann A, Mouatt-Prigent A, Faucheux BA, Agid Y, Hirsch EC. FADD: a link between TNF family receptors and caspases in Parkinson's disease. Neurology. 2002;58:308-310.
116. Hashimoto M, Takeda A, Hsu LJ, Takenouchi T, Masliah E. Role of cytochrome c as a stimulator of α-synuclein aggregation in Lewy body disease. J Biol Chem. 1999;274:28849-28852.
117. Schapira AH, Cooper JM, Dexter D, Clark JB, Jenner P, Marsden CD. Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem. 1990;54:823-827.
118. Di Monte DA. The environment and Parkinson's disease: is the nigrostriatal system preferentially targeted by neurotoxins? Lancet Neurol. 2003;2:531-538.
119. Fleming L, Mann JB, Bean J, BriggleT, Sanchez-Ramos JR. Parkinson's disease and brain levels of organochlorine pesticides. Ann Neurol. 1994;36:100-103.
120. Corrigan FM, Wienburg CL, Shore RF, Daniel SE, Mann D. Organochlorine insecticides in substantia nigra in Parkinson's disease. J Toxicol Environ Health A. 2000;59:229-234.
121. Corrigan FM, Murray L, Wyatt CL, Shore RF. Diorthosubstituted polychlorinated biphenyls in caudate nucleus in Parkinson's disease. Exp Neurol. 1998;150:339-342.
122. Corrigan FM, French M, Murray L. Organochlorine compounds in human brain. Hum Exp Toxicol. 1996;15:262-264.
123. Uversky VN, Li J, Fink AL. Pesticides directly accelerate the rate of a-synuclein fibril formation: a possible factor in Parkinson's disease. FEBS Lett. 2001;500:105-108.
124. Takahashi M, Yamada T. A possible role of influenza A virus infection for Parkinson's disease. Adv Neurol. 2001;86:91-104.
125. Chapman G, Beaman BL, Loeffler DA, et al. In situ hybridization for detection of nocardial 16S rRNA: reactivity within intracellular inclusions in experimentally infected cynomolgus monkeys-and in Lewy body-containing human brain specimens. Exp Neurol. 2003;184:715-725.
126. Kennedy PG. Neurovirological methods and their applications. J Neurol Neurosurg Psychiatry. 2003;74:1016-1022.
127. Rub U, Del Tredici K, Schultz C, et al. Parkinson's disease: the thalamic components of the limbic loop are severely impaired by α-synuclein immunopositive inclusion body pathology. Neurobiol Aging. 2002;23:245-254.
128. Emre M. What causes mental dysfunction in Parkinson's disease? Mov Disord. 2003;18(suppl 6):S63-S71.
129. Wakabayashi K, Takahashi H. Neuropathology of autonomie nervous system in Parkinson's disease. Eur Neurol. 1997;38(suppl 2):2-7.
130. Lai YY, Siegel JM. Physiological and anatomical link between Parkinson-like disease and REM sleep behavior disorder. Mol Neurobiol. 2003;27:137-152.
131. Braak H, Rub U, Gai WP, Del Tredici K. Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neural Transm. 2003;110:517-536.
132. Del Tredici K, Rub U, De Vos RA, Bohl JR, Braak H. Where does Parkinson disease pathology begin in the brain? J Neuropathol Exp Neurol. 2002;61:413-426.
133. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003;24:197-211.
134. Hardy J, Cookson MR, Singleton A. Genes and parkinsonism. Lancet Neurol. 2003;2:221-228.
135. Chen H, Zhang SM, Hernan MA, et al. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch Neurol. 2003;60:1059-1064.
136. Murphy DD, Ravina B. Brain banking for neurodegenerative diseases. Curr Opin Neurol. 2003;16:459-463.